When dividing patients into separate groups, depending on the type of leukemia (ALL, AML, and CML), the number of subjects analyzed in each group was limited, and highly variable factors such as KIR genotypes did not allow the comparison of each subgroup of leukemia with healthy controls. This evidence concerns the gene KIR3DL1 and leukemia.